JP2013500721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013500721A5 JP2013500721A5 JP2012523041A JP2012523041A JP2013500721A5 JP 2013500721 A5 JP2013500721 A5 JP 2013500721A5 JP 2012523041 A JP2012523041 A JP 2012523041A JP 2012523041 A JP2012523041 A JP 2012523041A JP 2013500721 A5 JP2013500721 A5 JP 2013500721A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- seq
- binding protein
- nkg2d
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000023732 binding proteins Human genes 0.000 claims 65
- 108091008324 binding proteins Proteins 0.000 claims 65
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 45
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 20
- 201000010099 disease Diseases 0.000 claims 17
- 208000011580 syndromic disease Diseases 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 208000019693 Lung disease Diseases 0.000 claims 10
- 230000001154 acute effect Effects 0.000 claims 10
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 9
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 9
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 9
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 9
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 9
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 9
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 9
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 8
- 238000000684 flow cytometry Methods 0.000 claims 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 8
- 210000000056 organ Anatomy 0.000 claims 8
- 206010020751 Hypersensitivity Diseases 0.000 claims 7
- 230000001684 chronic effect Effects 0.000 claims 7
- 230000001363 autoimmune Effects 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 201000004624 Dermatitis Diseases 0.000 claims 5
- 206010052779 Transplant rejections Diseases 0.000 claims 5
- 208000026935 allergic disease Diseases 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 230000002757 inflammatory effect Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 238000002054 transplantation Methods 0.000 claims 5
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 4
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 4
- 206010015150 Erythema Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 4
- 231100000321 erythema Toxicity 0.000 claims 4
- 208000006454 hepatitis Diseases 0.000 claims 4
- 231100000283 hepatitis Toxicity 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000026872 Addison Disease Diseases 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 3
- 208000031845 Pernicious anaemia Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 206010003119 arrhythmia Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 230000002490 cerebral effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000018631 connective tissue disease Diseases 0.000 claims 3
- 239000002872 contrast media Substances 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000007475 hemolytic anemia Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 3
- 230000003902 lesion Effects 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 230000000414 obstructive effect Effects 0.000 claims 3
- 201000004535 ovarian dysfunction Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- 210000003491 skin Anatomy 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims 2
- 208000015879 Cerebellar disease Diseases 0.000 claims 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- 208000012287 Prolapse Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010062164 Seronegative arthritis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000003444 anaesthetic effect Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- -1 anthracyclines Substances 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 230000009033 hematopoietic malignancy Effects 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000000366 juvenile effect Effects 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000020763 muscle atrophy Effects 0.000 claims 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000015124 ovarian disease Diseases 0.000 claims 2
- 231100000543 ovarian dysfunction Toxicity 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000009174 transverse myelitis Diseases 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- 208000023769 AA amyloidosis Diseases 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003226 Arteriovenous fistula Diseases 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 208000006740 Aseptic Meningitis Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 206010003671 Atrioventricular Block Diseases 0.000 claims 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 241000271566 Aves Species 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000000135 Cardiovascular Syphilis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010010941 Coombs positive haemolytic anaemia Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010011703 Cyanosis Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010072268 Drug-induced liver injury Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 1
- 208000035366 Familial hemophagocytic lymphohistiocytosis Diseases 0.000 claims 1
- 208000007984 Female Infertility Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010058872 Fungal sepsis Diseases 0.000 claims 1
- 201000000628 Gas Gangrene Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018498 Goitre Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000031856 Haemosiderosis Diseases 0.000 claims 1
- 208000025309 Hair disease Diseases 0.000 claims 1
- 206010019315 Heart transplant rejection Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 claims 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 206010021928 Infertility female Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 claims 1
- 206010058142 Intestine transplant rejection Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 1
- 241000589248 Legionella Species 0.000 claims 1
- 208000007764 Legionnaires' Disease Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010024715 Liver transplant rejection Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025282 Lymphoedema Diseases 0.000 claims 1
- 208000035809 Lymphohistiocytosis Diseases 0.000 claims 1
- 208000007466 Male Infertility Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027201 Meningitis aseptic Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010028665 Myxoedema Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 208000003076 Osteolysis Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033165 Ovarian failure Diseases 0.000 claims 1
- 206010053869 POEMS syndrome Diseases 0.000 claims 1
- 206010049169 Pancreas transplant rejection Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000025584 Pericardial disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 206010057244 Post viral fatigue syndrome Diseases 0.000 claims 1
- 206010052381 Primary adrenal insufficiency Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 201000003099 Renovascular Hypertension Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 206010038915 Retinitis viral Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039094 Rhinitis perennial Diseases 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 206010039807 Secondary adrenocortical insufficiency Diseases 0.000 claims 1
- 206010039811 Secondary amyloidosis Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000009714 Severe Dengue Diseases 0.000 claims 1
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 claims 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010061372 Streptococcal infection Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 241000607734 Yersinia <bacteria> Species 0.000 claims 1
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 208000018254 acute transverse myelitis Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 208000030597 adult Refsum disease Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000003263 anabolic agent Substances 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000002226 anterior horn cell Anatomy 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003092 anti-cytokine Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000002682 anti-psoriatic effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 210000000709 aorta Anatomy 0.000 claims 1
- 210000000702 aorta abdominal Anatomy 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 206010003668 atrial tachycardia Diseases 0.000 claims 1
- 208000001974 autoimmune enteropathy Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000018300 basal ganglia disease Diseases 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 210000004375 bundle of his Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 208000036319 cervical spondylosis Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000007870 cholestasis Effects 0.000 claims 1
- 231100000359 cholestasis Toxicity 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000002594 corticospinal effect Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000002950 dengue hemorrhagic fever Diseases 0.000 claims 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 claims 1
- 238000002224 dissection Methods 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008865 drug-induced hepatitis Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 210000000918 epididymis Anatomy 0.000 claims 1
- 201000010063 epididymitis Diseases 0.000 claims 1
- 210000002409 epiglottis Anatomy 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 108010074605 gamma-Globulins Proteins 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 201000003872 goiter Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 201000010235 heart cancer Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000024348 heart neoplasm Diseases 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 230000001660 hyperkinetic effect Effects 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000003483 hypokinetic effect Effects 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 208000037797 influenza A Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007919 intrasynovial administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 201000002364 leukopenia Diseases 0.000 claims 1
- 231100001022 leukopenia Toxicity 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000002502 lymphedema Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 201000006812 malignant histiocytosis Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 208000017972 multifocal atrial tachycardia Diseases 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 208000003786 myxedema Diseases 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 239000000842 neuromuscular blocking agent Substances 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 231100000539 ovarian failure Toxicity 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 208000015385 phacoanaphylactic uveitis Diseases 0.000 claims 1
- 208000001297 phlebitis Diseases 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 201000000317 pneumocystosis Diseases 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 208000019629 polyneuritis Diseases 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 208000000813 polyradiculoneuropathy Diseases 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000010349 pulsation Effects 0.000 claims 1
- 239000012217 radiopharmaceutical Substances 0.000 claims 1
- 229940121896 radiopharmaceutical Drugs 0.000 claims 1
- 230000002799 radiopharmaceutical effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 208000004124 rheumatic heart disease Diseases 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 210000003786 sclera Anatomy 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 230000002784 sclerotic effect Effects 0.000 claims 1
- 208000023087 secondary adrenal insufficiency Diseases 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 208000005801 spondylosis Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000002537 thrombolytic effect Effects 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 208000027185 varicose disease Diseases 0.000 claims 1
- 230000003156 vasculitic effect Effects 0.000 claims 1
- 208000037997 venous disease Diseases 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
- 208000003663 ventricular fibrillation Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22958609P | 2009-07-29 | 2009-07-29 | |
| US61/229,586 | 2009-07-29 | ||
| US25279009P | 2009-10-19 | 2009-10-19 | |
| US61/252,790 | 2009-10-19 | ||
| PCT/US2010/043716 WO2011014659A2 (en) | 2009-07-29 | 2010-07-29 | Dual variable domain immunoglobulins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013500721A JP2013500721A (ja) | 2013-01-10 |
| JP2013500721A5 true JP2013500721A5 (cg-RX-API-DMAC7.html) | 2013-09-19 |
Family
ID=43529940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523041A Withdrawn JP2013500721A (ja) | 2009-07-29 | 2010-07-29 | 二重可変ドメイン免疫グロブリンおよびその使用 |
Country Status (17)
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| BRPI0910482A2 (pt) | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
| AU2009256246B2 (en) * | 2008-06-03 | 2013-07-18 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| EP2297209A4 (en) * | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| BRPI0915448A2 (pt) | 2008-07-08 | 2015-11-10 | Abbott Lab | imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas |
| BRPI0922807A2 (pt) * | 2008-12-04 | 2015-12-22 | Abbott Lab | imonuglobulinas de domínio variável duplo e usos dos mesmos |
| JP5587975B2 (ja) * | 2009-04-07 | 2014-09-10 | ロシュ グリクアート アクチェンゲゼルシャフト | 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体 |
| CN102741288B (zh) | 2009-08-29 | 2015-08-19 | Abbvie公司 | 治疗用dll4结合蛋白 |
| JP2013503607A (ja) | 2009-09-01 | 2013-02-04 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
| MX2012004415A (es) | 2009-10-15 | 2012-05-08 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| KR101853278B1 (ko) | 2010-03-02 | 2018-05-02 | 애브비 인코포레이티드 | 치료학적 ｄｌｌ４ 결합 단백질 |
| JP2013537415A (ja) | 2010-08-03 | 2013-10-03 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| CN103260639A (zh) | 2010-08-26 | 2013-08-21 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| DK2646470T3 (en) * | 2010-11-30 | 2017-05-08 | Hoffmann La Roche | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER |
| TWI743461B (zh) * | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| MX366923B (es) * | 2011-03-28 | 2019-07-31 | Sanofi Sa | Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento. |
| JP5588086B2 (ja) | 2011-04-19 | 2014-09-10 | メリマック ファーマシューティカルズ インコーポレーティッド | 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体 |
| WO2013032943A1 (en) * | 2011-08-26 | 2013-03-07 | The Regents Of The University Of California | Methods and compositions for the treatment of respiratory conditions via nkg2d inhibition |
| AU2012362370A1 (en) * | 2011-12-30 | 2014-07-24 | Abbvie Inc. | Dual variable domain immunoglobulins against receptors |
| UY34558A (es) | 2011-12-30 | 2013-07-31 | Abbvie Inc | Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17 |
| RU2487719C1 (ru) * | 2012-05-24 | 2013-07-20 | Общество с ограниченной ответственностью "ВИТАЛАНГ" | Средство для лечения заболеваний с реакциями гиперчувствительности замедленного типа в патогенетическом процессе |
| HK1212448A1 (en) | 2012-09-07 | 2016-06-10 | The Governors Of The University Of Alberta | Methods and compositions for diagnosis of inflammatory liver disease |
| KR20210111353A (ko) | 2012-11-01 | 2021-09-10 | 애브비 인코포레이티드 | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| AU2014227732A1 (en) | 2013-03-15 | 2015-09-17 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 beta and IL-17 |
| HK1220214A1 (zh) | 2013-03-15 | 2017-04-28 | Abbvie Biotherapeutics Inc. | Fc变体 |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| KR102098985B1 (ko) | 2013-05-03 | 2020-04-09 | 오하이오 스테이트 이노베이션 파운데이션 | Cs1-특이적 키메라 항원 수용체 가공된 면역 작동체 세포 |
| WO2015035044A2 (en) | 2013-09-04 | 2015-03-12 | Abbvie Biotherapeutics Inc. | Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| ES2792682T3 (es) | 2014-02-10 | 2020-11-11 | Respivant Sciences Gmbh | Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos |
| EP3653207A1 (en) | 2014-02-10 | 2020-05-20 | Respivant Sciences GmbH | Mast cell stabilizers treatment for systemic disorders |
| UY36032A (es) | 2014-03-14 | 2015-10-30 | Novartis Ag | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas |
| CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| JP6708635B2 (ja) | 2014-10-09 | 2020-06-10 | エンクマフ エスアーエールエル | ＣＤ３εおよびＲＯＲ１に対する二特異性抗体 |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| US10544220B2 (en) | 2015-01-08 | 2020-01-28 | Genmab A/S | Bispecific antibodies against CD3 and CD20 |
| CN107530424A (zh) * | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| KR101943989B1 (ko) | 2015-06-05 | 2019-01-30 | 삼성전자주식회사 | 데이터를 송수신하는 방법, 서버 및 단말기 |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| RS62108B1 (sr) | 2016-03-02 | 2021-08-31 | Eisai R&D Man Co Ltd | Antitelo-lek konjugati na bazi eribulina i postupci primene |
| JP2019528320A (ja) | 2016-08-31 | 2019-10-10 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | 特発性肺線維症による慢性咳の治療のためのクロモリン組成物 |
| CA3037746A1 (en) | 2016-10-07 | 2018-04-12 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of pulmonary fibrosis |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN110494445B (zh) | 2017-01-06 | 2023-10-20 | Abl生物公司 | 抗α-SYN抗体及其用途 |
| KR20250089564A (ko) * | 2017-02-08 | 2025-06-18 | 드래곤플라이 쎄라퓨틱스, 인크. | 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도 |
| JP2020507577A (ja) * | 2017-02-10 | 2020-03-12 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 |
| SG11201907253VA (en) * | 2017-02-10 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding bcma, nkg2d and cd16 |
| EP3583133A4 (en) * | 2017-02-20 | 2021-04-14 | Dragonfly Therapeutics, Inc. | GD2, NKG2D AND CD16 BINDING PROTEINS |
| KR20190120782A (ko) * | 2017-02-20 | 2019-10-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| US20210130471A1 (en) * | 2017-02-20 | 2021-05-06 | Dragonfly Therapeutics, Inc. | Proteins binding cd33, nkg2d and cd16 |
| SG10202011219YA (en) * | 2017-02-27 | 2020-12-30 | Dragonfly Therapeutics Inc | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 |
| EP3630181A4 (en) * | 2017-05-23 | 2021-03-17 | Dragonfly Therapeutics, Inc. | NKG2D BINDING PROTEIN, CD16 AND TUMOR ASSOCIATED ANTIGEN |
| CA3064714A1 (en) * | 2017-05-23 | 2018-11-29 | Dragonfly Therapeutics, Inc. | A protein binding nkg2d, cd16 and a tumor-associated antigen |
| WO2019028027A1 (en) * | 2017-07-31 | 2019-02-07 | Dragonfly Therapeutics, Inc. | PROTEINS BINDING TO NKG2D, CD16 AND FLT3 |
| JP2020531438A (ja) * | 2017-08-16 | 2020-11-05 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、およびｅｇｆｒ、ｈｌａ−ｅ、ｃｃｒ４、またはｐｄ−ｌ１に結合するタンパク質 |
| MX2020002036A (es) * | 2017-08-23 | 2020-03-24 | Dragonfly Therapeutics Inc | Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor. |
| SG10202102502VA (en) * | 2017-09-07 | 2021-04-29 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| CN107807130A (zh) * | 2017-11-29 | 2018-03-16 | 周大生珠宝股份有限公司 | 环形光源钻石测量仪及钻石测量方法 |
| WO2019117685A2 (ko) * | 2017-12-14 | 2019-06-20 | 에이비엘바이오 주식회사 | 항-igf1r 항체 및 그 용도 |
| PE20210375A1 (es) | 2018-02-08 | 2021-03-02 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| CA3135711A1 (en) * | 2018-04-03 | 2019-10-10 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams |
| JP2021523140A (ja) * | 2018-05-07 | 2021-09-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合するタンパク質 |
| WO2019222449A1 (en) * | 2018-05-16 | 2019-11-21 | Dragonfly Therapeutics, Inc. | Protein binding nkg2d, cd16 and a fibroblast activation protein |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| US20210205411A1 (en) * | 2018-05-28 | 2021-07-08 | Orion Biotechnology Switzerland Sàrl | Ccr5 inhibitor for use in treating cancer |
| BR112021002276A2 (pt) * | 2018-08-08 | 2021-05-04 | Dragonfly Therapeutics, Inc. | proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor |
| EA202091888A1 (ru) * | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3108427A1 (en) * | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EP3938397A1 (en) * | 2019-03-14 | 2022-01-19 | Biond Biologics Ltd. | Small shedding blocking agents |
| CN110045099B (zh) * | 2019-04-01 | 2022-03-04 | 四川大学华西医院 | 一种慢性阻塞性肺疾病检测试剂盒 |
| US12157771B2 (en) | 2020-05-06 | 2024-12-03 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| JP2023524149A (ja) | 2020-05-08 | 2023-06-08 | ジェンマブ エー／エス | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| JP2023541858A (ja) | 2020-09-10 | 2023-10-04 | ジェンマブ エー／エス | 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| BR112023004351A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar linfoma folicular em um sujeito humano |
| MX2023002542A (es) | 2020-09-10 | 2023-03-15 | Genmab As | Anticuerpo biespecifico contra cumulo de difirenciacion 3 (cd3) y cumulo de difirenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes. |
| BR112023004216A2 (pt) | 2020-09-10 | 2023-04-11 | Genmab As | Método para tratar linfoma folicular em um sujeito humano |
| BR112023004321A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar linfoma de célula b grande difusa em um sujeito humano |
| TW202228775A (zh) | 2020-10-14 | 2022-08-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物及方法 |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| US20230084477A1 (en) | 2021-08-10 | 2023-03-16 | Viridian Therapeutics, Inc. | Compositions, doses, and methods for treatment of thyroid eye disease |
| CN117451995A (zh) * | 2021-12-06 | 2024-01-26 | 上海市精神卫生中心（上海市心理咨询培训中心） | 用于预测应激后精神心理症状发生的免疫检测试剂盒及应用 |
| TW202509073A (zh) | 2023-05-15 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 高度純化之依可利單抗組成物 |
| TW202508630A (zh) | 2023-05-15 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 治療表現ｃｄ２０之ｂ細胞癌症之方法 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US699473A (en) * | 1902-02-03 | 1902-05-06 | Thomas R Austin | Type-writer. |
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US6492107B1 (en) * | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| DE3546806C2 (cg-RX-API-DMAC7.html) * | 1985-03-30 | 1991-03-28 | Marc Genf/Geneve Ch Ballivet | |
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) * | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1992002551A1 (en) * | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| JPH06507404A (ja) * | 1991-05-01 | 1994-08-25 | ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
| DE4122599C2 (de) * | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| TW203552B (en) * | 1992-02-18 | 1993-04-11 | J Baroody Lloyd | Compositions of clindamycin and benzoyl peroxide for acne treatment |
| US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5516637A (en) * | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| GB9504344D0 (en) * | 1995-03-03 | 1995-04-19 | Unilever Plc | Antibody fragment production |
| US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6019968A (en) * | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| CA2230494A1 (en) * | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics Inc. | Composition for sustained release of an agent |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| WO1997029131A1 (en) * | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
| US5714352A (en) * | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| DE69730209T2 (de) * | 1996-04-04 | 2005-04-14 | Unilever N.V. | Multivalentes und multispezifisches Antigenbindungsprotein |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6699658B1 (en) * | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US5916771A (en) * | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6986890B1 (en) * | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
| US6057098A (en) * | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| CN1423700A (zh) * | 2000-03-24 | 2003-06-11 | 麦克美特股份公司 | 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽 |
| EP1272647B1 (en) * | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| US7449308B2 (en) * | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| SK1152003A3 (en) * | 2000-06-29 | 2003-07-01 | Abbott Lab | Dual specificity antibodies and methods of making and using |
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| MXPA03011365A (es) * | 2001-06-13 | 2005-03-07 | Genmab As | Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr). |
| JPWO2003027151A1 (ja) * | 2001-09-25 | 2005-01-06 | 株式会社 免疫生物研究所 | 組換え抗オステオポンチン抗体およびその用途 |
| WO2003062375A2 (en) * | 2001-12-19 | 2003-07-31 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| RU2339647C2 (ru) * | 2002-08-19 | 2008-11-27 | Астразенека Аб | Антитела против моноцитарного хемоаттрактантного белка-1 (мср-1) и их применение |
| EP1944320A1 (en) * | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| WO2004106381A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| CN103880955A (zh) * | 2003-07-18 | 2014-06-25 | 安姆根有限公司 | 肝细胞生长因子的特异性结合物 |
| CA2531595C (en) * | 2003-07-28 | 2015-12-08 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
| US7662928B2 (en) * | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CA2537055A1 (en) * | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| EP2502935B1 (en) * | 2003-08-22 | 2017-03-29 | Biogen MA Inc. | Improved antibodies having altered effector function and methods for making the same |
| EP1697543B1 (en) * | 2003-11-21 | 2014-08-20 | ANP Technologies, Inc. | Asymmetrically branched polymer conjugates and microarray assays |
| US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| CN102942631B (zh) * | 2004-08-05 | 2015-03-25 | 健泰科生物技术公司 | 人源化抗c-met拮抗剂 |
| AU2005285347A1 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB0419424D0 (en) * | 2004-09-02 | 2004-10-06 | Viragen Scotland Ltd | Transgene optimisation |
| PT1784426E (pt) * | 2004-09-03 | 2012-03-06 | Genentech Inc | Antagonistas humanizados anti-beta7 e suas utilizações |
| AU2005291486A1 (en) * | 2004-10-01 | 2006-04-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Novel antibodies directed to the mammalian EAG1 ion channel protein |
| MX2007004437A (es) * | 2004-10-22 | 2007-06-20 | Amgen Inc | Metodos para el repliegue de anticuerpos recombinantes. |
| US7423128B2 (en) * | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| DK1853718T3 (en) * | 2005-02-15 | 2015-11-09 | Univ Duke | ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY |
| US8048992B2 (en) * | 2005-02-28 | 2011-11-01 | Institute For Antibodies Co., Ltd. | Anti-IgSF4 antibody and utilization of the same |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| NZ597168A (en) * | 2005-08-19 | 2013-07-26 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
| US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| BR122020020335B1 (pt) * | 2005-08-26 | 2023-10-03 | Roche Glycart Ag | Anticorpo anti-cd20, composição farmacêutica e uso |
| US7906116B2 (en) * | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| CN101528115B (zh) * | 2005-09-21 | 2014-06-25 | 加利福尼亚大学董事会 | 用于疼痛成像治疗的系统和方法 |
| MX2008011874A (es) * | 2006-03-17 | 2009-01-07 | Biogen Idec Inc | Composiciones estabilizadas de polipeptidos. |
| US20080118978A1 (en) * | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
| ATE533787T1 (de) * | 2006-06-02 | 2011-12-15 | Aveo Pharmaceuticals Inc | Hepatozytenwachstumsfaktor (hgf)-bindende proteine |
| AR061245A1 (es) * | 2006-06-06 | 2008-08-13 | Genentech Inc | Composiciones y metodos para la modulacion del desarrollo vascular |
| US20090182127A1 (en) * | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| EP2405270B1 (en) * | 2006-06-30 | 2013-07-17 | Merck Sharp & Dohme Corp. | IGFBP2-Biomarker |
| DK2097455T3 (en) * | 2006-11-02 | 2014-12-15 | Genentech Inc | HUMANIZED ANTI-FACTOR D ANTIBODIES |
| JP5721951B2 (ja) * | 2007-03-22 | 2015-05-20 | バイオジェン アイデック マサチューセッツ インコーポレイテッド | 抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用 |
| CN101977935A (zh) * | 2007-04-23 | 2011-02-16 | 惠氏公司 | 用于治疗和监测il-13相关病症的方法和组合物 |
| GB0708002D0 (en) * | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
| US8227201B2 (en) * | 2007-06-27 | 2012-07-24 | Board Of Trustees Of The Leland Stanford Junior University | BETA2-microglobulin and C reactive protein (CRP) as biomarkers for peripheral artery disease |
| DK2235064T3 (en) * | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
| BRPI0910482A2 (pt) * | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
| WO2010006059A1 (en) * | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 binding proteins and uses thereof |
| BRPI0915448A2 (pt) * | 2008-07-08 | 2015-11-10 | Abbott Lab | imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas |
| WO2010017103A2 (en) * | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| CA2737035A1 (en) * | 2008-09-30 | 2010-04-08 | Abbott Laboratories | Improved method of rna display |
| MX2011011670A (es) * | 2009-05-01 | 2011-11-18 | Abbott Lab | Inmunoglobulinas de dominio variable dual y usos de las mismas. |
| JP2013503607A (ja) * | 2009-09-01 | 2013-02-04 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
| MX2012004415A (es) * | 2009-10-15 | 2012-05-08 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| JP2013537415A (ja) * | 2010-08-03 | 2013-10-03 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| CN103260639A (zh) * | 2010-08-26 | 2013-08-21 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
-
2010
- 2010-07-28 UY UY0001032808A patent/UY32808A/es not_active Application Discontinuation
- 2010-07-28 TW TW099124965A patent/TW201109438A/zh unknown
- 2010-07-29 EP EP10805046.9A patent/EP2459729A4/en not_active Withdrawn
- 2010-07-29 AU AU2010278947A patent/AU2010278947A1/en not_active Abandoned
- 2010-07-29 US US12/846,317 patent/US20110044980A1/en not_active Abandoned
- 2010-07-29 MX MX2012001262A patent/MX2012001262A/es not_active Application Discontinuation
- 2010-07-29 AR ARP100102767A patent/AR078087A1/es not_active Application Discontinuation
- 2010-07-29 CA CA2769518A patent/CA2769518A1/en not_active Abandoned
- 2010-07-29 KR KR1020127005103A patent/KR20120047274A/ko not_active Withdrawn
- 2010-07-29 JP JP2012523041A patent/JP2013500721A/ja not_active Withdrawn
- 2010-07-29 WO PCT/US2010/043716 patent/WO2011014659A2/en not_active Ceased
- 2010-07-29 SG SG2012006243A patent/SG178148A1/en unknown
- 2010-07-29 RU RU2012107526/10A patent/RU2012107526A/ru not_active Application Discontinuation
- 2010-07-29 CN CN2010800434689A patent/CN102791875A/zh active Pending
- 2010-07-29 BR BRBR112012002095-1A patent/BR112012002095A2/pt not_active IP Right Cessation
-
2012
- 2012-01-24 IL IL217718A patent/IL217718A0/en unknown
- 2012-01-26 ZA ZA2012/00666A patent/ZA201200666B/en unknown